StockData
Caribou Biosciences, Inc. logo

Caribou Biosciences, Inc. (CRBU) stock

CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3074% below fair value
$0.33−0.01 (-4.29%)

Close on Nov 18, 2026Market cap $34.96MP/E –Yield –

Caribou Biosciences revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Caribou Biosciences's revenue for the twelve months ending Jun 30, 2026 was $10.04M, up 10.0% year over year. For fiscal 2025 it was $11.16M, up 11.7% from the year before. The highest annual figure on record is $34.48M in fiscal 2023.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$11.16M+11.7%
FY2024Dec 31, 2024$9.99M-71.0%
FY2023Dec 31, 2023$34.48M+148.9%
FY2022Dec 31, 2022$13.85M+44.3%
FY2021Dec 31, 2021$9.60M-22.4%
FY2020Dec 31, 2020$12.36M+113.6%
FY2019Dec 31, 2019$5.79M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.50M-43.8%
Q1 FY2026Mar 31, 2026$2.40M+1.9%
Q4 FY2025Dec 31, 2025$3.94M+89.7%
Q3 FY2025Sep 30, 2025$2.20M+8.6%
Q2 FY2025Jun 30, 2025$2.67M-23.0%
Q1 FY2025Mar 31, 2025$2.35M-3.1%
Q4 FY2024Dec 31, 2024$2.08M-41.6%
Q3 FY2024Sep 30, 2024$2.02M-91.4%
Q2 FY2024Jun 30, 2024$3.46M-7.7%
Q1 FY2024Mar 31, 2024$2.43M-30.6%
Q4 FY2023Dec 31, 2023$3.56M-3.6%
Q3 FY2023Sep 30, 2023$23.66M+616.4%
Q2 FY2023Jun 30, 2023$3.76M-10.4%
Q1 FY2023Mar 31, 2023$3.50M+31.5%
Q4 FY2022Dec 31, 2022$3.69M+44.3%
Q3 FY2022Sep 30, 2022$3.30M-16.9%
Q2 FY2022Jun 30, 2022$4.19M+184.0%
Q1 FY2022Mar 31, 2022$2.66M+68.0%
Q4 FY2021Dec 31, 2021$2.56M+160.1%
Q3 FY2021Sep 30, 2021$3.98M+232.0%
Q2 FY2021Jun 30, 2021$1.48M-82.6%
Q1 FY2021Mar 31, 2021$1.59M-6.8%
Q4 FY2020Dec 31, 2020$984.00K–
Q3 FY2020Sep 30, 2020$1.20M–
Q2 FY2020Jun 30, 2020$8.48M–
Q1 FY2020Mar 31, 2020$1.70M–

More Caribou Biosciences figures

See a number that looks wrong?